

Case Report

Langerhans cell proliferation in micronodular thymic carcinoma with lymphoid stroma: report of a rare case

Pengcheng Zhu^{1,2}, Yue'e Wang^{1,2}, Lei Cai^{1,2}, Fei Yan³, Qilin Ao^{1,2}, Guoping Wang^{1,2}

¹*Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology;*

²*Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;* ³*Department of Oncology, Zhongshan Hospital of Hubei Province, Wuhan, China*

Received July 19, 2016; Accepted September 15, 2016; Epub November 15, 2016; Published November 30, 2016

Abstract: Micronodular thymic carcinoma (MNCA) is an extremely rare variant of thymic carcinoma. We described a 67-year-old woman, who was referred to our institution for a mediastinal mass. The magnetic resonance imaging (MRI) scan showed a 5.0 cm × 4.1 cm × 2.2 cm infiltrative mass invading adjacent tissue with central cystic change. Histologically, the neoplasm was composed of epithelial tumor cells arranged in a micronodular growth pattern set in a stroma showing lymphoid hyperplasia with germinal centers. Contrary to micronodular thymoma-the benign micronodular thymic neoplasm, the epithelial cell component of the present case showed malignancy characterized by cytological atypia, increased mitotic activity and immunoactivity of CD5 and CD117. The lymphoid component was mixed mature B- and T-cells. Langerhans cells proliferation were confirmed within epithelial nodules with langerin, S-100, CD1a expression. We report a case of MNCA to emphasize the histopathologic features and the Langerhans cells proliferation and differential diagnosis of the rare lesion to promote a better and broader understanding of the morphologic spectrum of micronodular thymic neoplasm.

Keywords: Thymic carcinoma, micronodular, langerhans cell

Introduction

Micronodular thymic neoplasm was an uncommon variant of thymic tumors. The majority of cases in literatures are micronodular thymoma (MNT) with lymphoid hyperplasia known for its benign behavior. Malignant micronodular thymic neoplasm, first described by Weissferdt A et al in 2012 [1], were described as micronodular thymic carcinoma (MNCA) with lymphoid hyperplasia or thymic carcinoma with micronodular growth pattern fewer than 10 cases in English literatures [1, 2]. Histologically, the neoplasm was composed of epithelial tumor cells arranged in a micronodular growth pattern set in a stroma showing lymphoid hyperplasia with germinal centers. Contrary to MNT-the benign micronodular thymic neoplasm, the epithelial component of MNCA showed malignancy characterized by cytological atypia, increased mitotic activity and immunoactivity of CD5 and CD117 [1]. Here we presented a case of micronodular thymic carcinoma with lymphoid hyperplasia in stroma, and Langer-

hans cells proliferation within epithelial components was confirmed in the present case. To our best knowledge, it is the first case of MNCA with Langerhans cells proliferation in epithelial components in the literature. The study was approved by the Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Written informed consent was obtained from the patient.

Material and methods

Patient and tumor

A 67-year-old, previously healthy Chinese woman underwent a routine physical examination one week ago, and a mass was discovered in her superior mediastinum with ultrasound examination and computed tomography (CT) and MRI. The patient declared no history of myasthenia gravis or other autoimmune disorder, and subsequently surgical resection of the mediastinal mass was performed.

Table 1. Antibodies and dilutions used in the evaluation of micronodular thymic carcinoma

Antibody	Dilution	Source
P63	1:25	Novocastra
CK5/6	1:200	ZYMED
AE1/AE3	1:20	Dako
EMA	1:50	Dako
Langerin	1:100	Novocastra
Cd1a	1:100	Dako
S-100	1:1000	Dako
CD3	1:20	Novocastra
CD5	1:50	Novocastra
CD117	1:200	Dako
CD20	1:2000	Dako
TdT	1:50	Dako
CD99	1:50	Dako
KI67	1:30	Novocastra

Histology and immunohistochemistry

The specimens were fixed in 4% formalin and embedded in paraffin. Sections were cut and stained with hematoxylin & eosin (H & E) routinely. Immunohistochemical stains were performed by an enhancement method based on the pressure-cooking-based antigen retrieval of slides that were placed into 0.01 M citrate buffer at pH 6.0 on 5- μ m sections cut from paraffin blocks. Binding of primary antibodies was visualized with an Envision two-step method. Diaminobenzidine was used as the chromogen. Nuclei were stained with Mayer's hematoxylin. The antibodies applied are given in **Table 1**.

Results

Grossly, the mass measured 5.0 cm \times 4.1 cm \times 2.2 cm in size. The cut surface was grey-white in color with central cystic change, and invasion into adjacent tissue was observed without a clear fibrous capsule. Microscopically, on low power, the histological finding was a micronodular growth pattern characterized by multiple epithelial cell nodules separated by an abundant lymphoid stroma with germinal centers in peripheral zone (**Figure 1A**) and by fibrous to hyaline stroma with few lymphoid cell infiltration in central zone (**Figure 1C**); while on high power, the epithelial cells showed large and oval to polygonal shaped with vesicular nuclei, conspicuous nucleoli and abundant pale cytoplasm. Mitoses varied from 5 to 8 per 10 high

power fields, and no necrosis or keratinization was present (**Figure 1B, 1C**).

Immunohistochemical stains showed the nodular epithelioid component positive for CK5/6, CKpan, CD5 (**Figure 1D**) and CD117 (**Figure 1E**) in peripheral zone, as well as in central zone; the lymphoid stroma in peripheral zone was composed mainly of mature B lymphocytes (CD20+) especially highlighting the follicles and germinal centers. Mature CD3+/TdT- T-lymphocytes were also numerous without immature T cells presence. Some langerin+ (**Figure 1F**), S-100+, CD1a+ cells were scattered within epithelial cell micronodules.

The diagnosis of micronodular thymic carcinoma with lymphoid stroma was made. Follow-up revealed that the patient was alive and well 20 months without recurrence after initial diagnosis.

Discussion

Micronodular thymoma (MNT) with lymphoid B-cell hyperplasia is a rare variant of thymoma, characterized by numerous epithelial nodules of spindle morphology, mixed in lymphoid stroma, even with lymphoid follicles and germinal center [3, 4]. MNT displays a benign behavior with no cell atypia, increasing mitosis and necrosis. Micronodular thymic carcinoma (MNCA) with lymphoid hyperplasia was more recently described as the malignant counterpart of micronodular thymoma with lymphoid B-cell hyperplasia [1] (**Table 2**). A series of reports gave support to the theory that micronodular thymic tumors with follicular lymphoid hyperplasia had a morphologic spectrum from completely benign micronodular thymoma with lymphoid B-cell hyperplasia to malignant micronodular thymic carcinoma with lymphoid hyperplasia, although there was no an entity of micronodular thymic carcinoma in the newest list of WHO thymic tumors classification [5, 6].

In the present case, on low-power microscopic view, histological findings in the peripheral zone of the lesion showed a typical micronodular growth pattern characterized by multiple small tumor nodules or sheet-like, elongated areas of epithelial components separated by an abundant lymphoid stroma with lymphoid follicles and germinal center. While the abundant lymphoid stroma became less when transitioned




Figure 1. A. The tumor showed a micronodular growth pattern characterized by multiple epithelial cell nodules separated by an abundant lymphoid stroma with germinal centers in peripheral zone (left) and by fibrous to hyaline stroma with few lymphoid cell infiltration in central zone (right) (H & E, $\times 100$); B. The tumor showed micronodular growth pattern characterized by multiple epithelial cell nodules separated by an abundant lymphoid stroma with germinal centers: epithelial cells showed large and oval to polygonal shaped with vesicular nuclei, conspicuous nucleoli and abundant pale cytoplasm. Mitoses varied from 5 to 8 per 10 high power fields (H & E, $\times 200$); C. The epithelial components showed trabecular growth pattern with less micronodular structures in the central zone and the lymphoid stroma replaced by fibrous to hyaline one (H & E, $\times 200$); D. The epithelial component was positive for CD5 in peripheral zone (left), as well as in central zone (right) ($\times 200$); E. The epithelial component was positive for CD 117 in peripheral zone (left), as well as in central zone (right) ($\times 200$); F. Langerhans cells were scattered in the epithelial nodules with langerin positivity ($\times 200$).

to the central zone and replaced by fibrous and hyaline stroma with little lymphoid tissue. The

epithelial components showed trabecular growth pattern with less micronodular structures

Table 2. Micronodular thymic carcinoma with micronodular growth pattern cases reported in literature

First author	Cases	Age/sex	Sites	Size (diameter)	Diagnosis	Time
Weissferdt A	5	Mean 64 ys/2 F, 3 M	thymus	3.2-10 cm	MNC	2012
WS Mneimneh	1	75 ys/F	thymus	NS	MNC	2015

MNC: micronodular carcinoma; ys: years; F: female; M: male; NS: not stated.

in the central zone of the lesion. These histological findings were different to the previous reports of MNCA with solely micronodular pattern. On high power examination, the epithelial cells of the micronodules showed spindle to round or oval shaped with vesicular nuclei and abundant pale eosinophilic cytoplasm with atypia and increasing mitotic activity (5-8/10 HPFs) compared with bland appearance of epithelial cells in classical MNT [7]. There was no necrosis or keratinization presence in this case.

Immunohistochemical stain showed positivity of CD5 and CD117 and higher proliferation index of the epithelial components in both peripheral and central zone also gave support to the diagnosis of MNCA other than MNT. We were interested in whether there were Langerhans cells proliferation or not in the epithelial components of this case since we had confirmed the phenomenon in a rare ectopic MNT [8], and the Langerhans cells proliferation was observed in six MNT cases from other group at the mean time [9]. The immunohistochemical stain of langerin in the present case showed that Langerhans cells proliferation could be observed in the epithelial components not only in the micronodules in peripheral zone but also in the epithelial trabecula in the central zone, and the density of Langerhans cells in peripheral zone is relatively higher than in the central zone. It was known that the Langerhans cells originated from the bone marrow and then migrated into different parts of the body to perform the function of antigen recognition and presentation. It was hypothesized that the Langerhans cells proliferation reflects a host immune reaction against epithelial tumoral antigens [9]. We had no idea about the clinical importance of the Langerhans cells proliferation in micronodular thymic neoplasms by far. Further study would be carried out to detect the Langerhans cells proliferation in the thymic neoplasms including not only more cases of MNCA and MNT but also other subtypes of thymic neoplasms. The role of Langerhans cells in the thymic neoplasm could be clarified then.

Lymphoid hyperplasia with germinal centers of the stroma in the present case reflected the host immune response in reaction to tumor epithelial antigens, which is believed to be beneficial, leading to the improved survival [10, 11]. It was reported that the malignant transformation may also occur in the lymphoid component of micronodular thymic neoplasms, the extranodal marginal cell lymphoma and follicular lymphoma were two common subtype of the malignant transformation of the lymphoid stroma of the micronodular thymic neoplasms [3]. In the present case, there was no morphological and immunohistochemical evidences of the malignant transformation of the lymphoid stroma but mixed mature B cells with germinal center formation and some mature T cells without TdT expression in peripheral zone, and the lymphoid stroma was replaced by the fibrous and hyaline stroma in the central zone of the tumor.

Since MNCA was an extremely rare tumor, awareness of potential diagnostic pitfalls is important for the correct diagnosis. MNT should be the first differential diagnostic consideration for MNCA. As a benign one of micronodular thymic neoplasm, MNT showed no cellular atypia and low mitotic activity without CD5 and CD117 expression in epithelial components [12], and necrosis was not seen in the MNT. The other subtypes of thymoma including type B3 thymoma and type A thymoma could be the diagnostic pitfalls for their epithelial components proliferation mimicking the micronodules in MNCA. Both two subtypes of thymoma could be ruled out easily in the present case for its distinct micronodular structure with lymphoid stroma [5]. The lymphoepithelioma-like thymic carcinoma or spindle cell 'sarcomatoid' carcinoma should be also considered as differential diagnosis [13, 14]. The lymphoepithelioma-like thymic carcinoma had histologic features similar to lymphoepithelioma-like carcinoma of the nasopharynx with sheets of large cells with vesicular nuclei and prominent eosinophilic nucleoli with a scant and indistinct rim of cytoplasm and lymphocytes in the stroma may be

dense or may not be present [15]. Spindle cell 'sarcomatoid' carcinoma of thymus showed spindle and pleomorphic cells with hyperchromatic nuclei, prominent nucleoli, and numerous mitoses and few lymphocytes in the stroma [16].

In summary, we present a very rare case of micronodular thymic carcinoma with lymphoid stroma and confirmed Langerhans cells proliferation in the epithelial nodules. Awareness of the existence of micronodular thymic carcinoma is important for the differential diagnosis of thymic neoplasms in order not to confuse the rare tumor for its histological features to mimics lesions. Accumulation of the MNCA cases and longer follow-up may further obtain more data regarding the prognosis for patients with this lesion.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Qilin Ao, Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefangdadao 1095, Wuhan 430030, China. Tel: 86-27-83663624; Fax: 86-27-83650729; E-mail: aoqilin@hust.edu.cn

References

- [1] Weissferdt A and Moran CA. Micronodular thymic carcinoma with lymphoid hyperplasia: a clinicopathological and immunohistochemical study of five cases. *Mod Pathol* 2012; 25: 993-999.
- [2] Mneimneh WS, Gökmen-Polar Y, Kesler KA, Loehrer PJ Sr, Badve S. Micronodular thymic neoplasms: case series and literature review with emphasis on the spectrum of differentiation. *Mod Pathol* 2015; 28: 1415-1427.
- [3] Strobel P, Marino M, Feuchtenberger M, Rouziere AS, Tony HP, Wulbrand U, Forster R, Zettl A, Lee Harris N, Kreipe H, Laeng RH, Muller-Hermelink HK and Marx A. Micronodular thymoma: an epithelial tumour with abnormal chemokine expression setting the stage for lymphoma development. *J Pathol* 2005; 207: 72-82.
- [4] Suster S and Moran CA. Micronodular thymoma with lymphoid B-cell hyperplasia: clinicopathologic and immunohistochemical study of eighteen cases of a distinctive morphologic variant of thymic epithelial neoplasm. *Am J Surg Pathol* 1999; 23: 955-962.
- [5] Marx A, Chan JK, Coindre JM, Detterbeck F, Girard N, Harris NL, Jaffe ES, Kurrer MO, Marom EM, Moreira AL, Mukai K, Orazi A and Strobel P. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. *J Thorac Oncol* 2015; 10: 1383-1395.
- [6] Antonicelli A and Detterbeck F. What's new in thymic neoplasms. *Curr Opin Pulm Med* 2015; 21: 327-332.
- [7] Chen CW, Chuang SS and Pan ST. Micronodular Thymoma with Lymphoid Stroma Diagnosed with Core Needle Biopsy. A Case Report. *Anal Quant Cytopathol Histopathol* 2015; 37: 206-210.
- [8] Zhu P, Yan F and Ao Q. Langerhans cells proliferation in ectopic micronodular thymoma with lymphoid stroma: a case report. *Int J Clin Exp Pathol* 2014; 7: 7262-7267.
- [9] Ishikawa Y, Tateyama H, Yoshida M, Takami K, Matsuguma H, Taniguchi T, Usami N, Kawaguchi K, Fukui T, Ishiguro F, Nakamura S and Yokoi K. Micronodular thymoma with lymphoid stroma: an immunohistochemical study of the distribution of Langerhans cells and mature dendritic cells in six patients. *Histopathology* 2015; 66: 300-307.
- [10] Tateyama H, Saito Y, Fujii Y, Okumura M, Nakamura K, Tada H, Yasumitsu T and Eimoto T. The spectrum of micronodular thymic epithelial tumours with lymphoid B-cell hyperplasia. *Histopathology* 2001; 38: 519-527.
- [11] Weksler B and Lu B. Alterations of the immune system in thymic malignancies. *J Thorac Oncol* 2014; 9: S137-142.
- [12] El MF, Braham E, Ayadi A, Ismail O and Kilani T. Micronodular thymoma with lymphoid stroma: report of two cases and particular association with thymic lymphoid hyperplasia in one case. *Pathology* 2006; 38: 586-588.
- [13] Marx A, Strobel P, Badve SS, Chalabreysse L, Chan JK, Chen G, de Leval L, Detterbeck F, Girard N, Huang J, Kurrer MO, Lauriola L, Marino M, Matsuno Y, Molina TJ, Mukai K, Nicholson AG, Nonaka D, Rieker R, Rosai J, Ruffini E and Travis WD. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. *J Thorac Oncol* 2014; 9: 596-611.
- [14] Mlika M, Boudaya S, Braham E, Chermiti F, Sayi A, Marghli A and El Mezni F. About thymic carcinomas: challenges in diagnosis and management. *Asian Cardiovasc Thorac Ann* 2016; 24: 350-4.
- [15] Rosai J. "Lymphoepithelioma-like" thymic carcinoma: another tumor related to Epstein-Barr virus? *N Engl J Med* 1985; 312: 1320-1322.
- [16] Sano I, Matsumoto H and Taniguchi H. [Thymic sarcomatoid carcinoma; report of a case]. *Kyobu Geka* 2013; 66: 517-519.